Home | Industry Information | Business News | Browse by Publication | F | FDA Consumer

Treating restless legs syndrome.(Disease/Disorder overview)

Publication: FDA Consumer
Publication Date: 01-MAY-06
Format: Online
Delivery: Immediate Online Access

Article Excerpt
Restless Legs Syndrome (RLS) is a medical condition characterized by unpleasant sensations in the legs, including burning, tugging, and tightening, and feels "like insects crawling inside the legs," according to the National Institute of Neurological Disorders and Stroke (NINDS).

Although...

View more below

Read this article now - Try Goliath Business News - FREE!   
You can view this article PLUS...

  • Over 5 million business articles
  • Hundreds of the most trusted magazines, newswires, and journals (see list)
  • Premium business information that is timely and relevant
  • Unlimited Access

Now for a Limited Time, try Goliath Business News - Free for 7 Days!
Tell Me More   Terms and Conditions

Purchase this article for $4.95

Already a subscriber? Log in to view full article

...experts have known about RLS for years, a broader lack of awareness appears to have severely limited diagnosis of the condition. A survey conducted by the Restless Legs Syndrome Foundation (RLSF) not only found that more than half of those who responded had never heard of RLS, but also found that many did not fully understand the impact that the condition can have on daily life.

"RLS is sometimes described as 'the most common condition you've never heard of,'" says Georgianna Bell, executive director of the RLSF.

The abnormal sensations (paresthesias) or unpleasant abnormal sensations (dysesthesias) often range from uncomfortable to irritating and painful.

The NINDS says that some researchers estimate that RLS affects as many as 12 million people in the United States. However, others estimate a much higher occurrence because RLS is thought to be underdiagnosed, and, in some cases, misdiagnosed. There are a number of people who don't seek medical attention, because they believe that their concerns will not be taken seriously, their symptoms are too mild, or their condition is not treatable.

In May 2005, the Food and Drug Administration approved the first drug treatment for RLS for which the cause is unknown (idiopathic). Called Requip (ropinirole), the drug is specifically labeled for the treatment of moderate-to-severe symptoms of the condition. According to the RLSF, the FDA's approval of Requip represents a significant step forward in patient care. "It is our hope that the millions of people suffering from RLS will benefit from this increased awareness and will more easily find the...

NOTE: All illustrations and photos have been removed from this article.



More articles from FDA Consumer
Take the FDA consumer quiz., May 01, 2006
Making multiple lifestyle changes can lower high blood pressure., May 01, 2006
New drug for chronic constipation.(Amitiza by Takeda Pharmaceuticals N..., May 01, 2006
Guidance on 'whole grain'.(Updates), May 01, 2006
First generic Flonase.(Roxane Laboratories Inc.), May 01, 2006

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.